An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

NCT06401356 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancy
Solid Tumor
Advanced Malignancies

Interventions

DRUG: Pelabresib

Sponsor

Novartis Pharmaceuticals